Home » Trials » SLCTR/2026/021


Evaluating the effectiveness of using two Vitamin D Supplementation regimes to improve glucose tolerance in vitamin D deficient Sri Lankan adults: A preliminary open labelled phase IV randomised trial

-

SLCTR Registration Number

SLCTR/2026/021


Date of Registration

13 Aug 2026

The date of last modification

Aug 13, 2026



Application Summary


Scientific Title of Trial

Evaluating the effectiveness of using two Vitamin D Supplementation regimes to improve glucose tolerance in vitamin D deficient Sri Lankan adults: A preliminary open labelled phase IV randomised trial


Public Title of Trial

Evaluating the effectiveness of using two Vitamin D Supplementation regimes to improve glucose tolerance in vitamin D deficient Sri Lankan adults: A preliminary open labelled phase IV randomised trial


Disease or Health Condition(s) Studied

Vitamin D deficiency and impaired glucose tolerance


Scientific Acronym

None


Public Acronym

None


Brief title

None


Universal Trial Number

U1111-1342-1787


Any other number(s) assigned to the trial and issuing authority

ERC/2026/62: ERC Rajarata


Trial Details


What is the research question being addressed?

Which of the two different regimens of vitamin D supplementation, in addition to lifestyle modification, would improve glucose tolerance in vitamin D-deficient Sri Lankan adults?


Type of study

Interventional


Study design

Allocation

Randomized controlled trial


Masking

Masking not used


Control

Dose comparison


Assignment

Parallel


Purpose

Prevention


Study Phase

Phase 4


Intervention(s) planned

Study setting – Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura

Study population – Adults residing in Anuradhapura district Sri Lanka. Adults with impaired glucose tolerance (IGT) as per the WHO criteria (fasting plasma glucose (< 126 mg/dL, 7 mmol/L) and 2-hour plasma glucose after a 75g of glucose load between 140 – 199 mg/dL (7.8 – 11.1 mmol/L)

Intervention Group 1 - 2,000 IU daily cholecalciferol (vitamin D3) for 24 weeks+ lifestyle modifications* Group 2 - 60,000 IU per week cholecalciferol (vitamin D3) for 8 weeks, followed by 2,000 IU/day cholecalciferol (vitamin D3) for 16 weeks + lifestyle modifications* *-lifestyle modifications include sun exposure, diet and level of physical activities

Sun exposure -Exposing at least 25-30% of body surface area (face, arms and legs) for direct sunlight without sunscreen daily for 30-35 minutes between 10.00 am to 3.00 pm,

Diet - The dietary pattern of the participants will be assessed based on the data obtained at the baseline assessment through 3-day food diary. Accordingly necessary dietary modification advices will be given based on food based dietary guidelines developed by Ministry of Health, Sri Lanka

Level of Physical activities - The advices will be provided based on the 2024 Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/American Stroke Association. Accordingly, the participants will be advised to engage in at least 150 minutes of moderate-intensity physical activity, 75 minutes of vigorous-intensity physical activity, or an equivalent combination per week and to avoid excessive time spent in sedentary behaviour (characterized by low energy expenditure while sitting, reclining, or lying while awake)

Randomization – block randomization Block randomization will be performed after recruitment of the required sample size. Initially, participants will be ranked in descending order based on baseline serum vitamin D levels to ensure comparable baseline distribution between groups. Subsequently, participants will be divided into 10 blocks, each comprising four individuals. Within each block, two participants will be assigned to each group. Allocation within each block will be determined using randomly selected sequences. All possible allocation arrangements (e.g., 1-1-2-2, 1-2-1-2, 2-2-1-1, 1-2-2-1, 2-1-1-2) will be written on paper chits. For each block, one chit will be randomly selected to determine the allocation sequence. After each selection, the chit will be returned to the pool to allow for random reuse in subsequent blocks.


Inclusion criteria

Adults (both males and females) aged 30-50 years Normal body mass index 18.5 – 22.9 kg/m² as per the South Asian cutoffs Vitamin D deficient (<20 ng/mL) or insufficient (21-29 ng/mL) Impaired glucose tolerance as of the results of oral glucose tolerance test (fasting plasma glucose (< 126 mg/dL) and 2- hour plasma glucose 140 – 199 mg/dL), Adults who can understand written and verbal communications in Sinhala or English languages


Exclusion criteria

Adults who have any acute or chronic illnesses and, on any medication, or supplementation (including vitamin D and calcium), Adults who have present or past history of nephrolithiasis, Pregnant and lactating mothers (though empiric vitamin D supplementation during pregnancy is recommended by the 2024 guidelines of American endocrine society this group will be excluded considering the significant effect of pregnancy related hormones on glucose homeostasis and the physical parameters measured in the study), Adults who consume alcohol or smoking, Menopaused females, Adults who will be detected to have hypercalcaemia, elevated liver enzymes (ALT, AST) and serum creatinine and parathyroid hormone levels at baseline investigations



Primary outcome(s)

1.

Changes in plasma glucose tolerance following vitamin D supplementation Method - assessment of plasma glucose level 2 hours after 75g oral glucose load (oral glucose tolerance test)

[

At the point of recruitment (baseline) and 24 weeks after the intervention (end of trial)

]

Secondary outcome(s)

1.

Changes in plasma glucose, insulin, and insulin sensitivity Method - assessing fasting plasma glucose, serum insulin and HOMA-IR score

[

At the point of recruitment and 24 weeks after (end of the intervention)

]
2.

Proportion achieving vitamin D sufficiency through two regimes after 10 weeks and 24 weeks of supplementation Method - calculating the percentage of participants who achieved the normal vitamin D levels

[

At the point of recruitment and 24 weeks after (end of the intervention)

]
3.

Adherence to supplementation Method - Treatment diary will be given to the participants at each follow up visit along with the required number of pills until next visit (monthly). participants will be advised to submit the remaining pills. Adherence will be measured using the treatment diary and the remaining pill count

[

At every follow up visit (at the end of 4th, 8th, 10th, 16th, 20th and 24th week)

]
4.

Tolerability and adverse events Method - Assessing the treatment diary, detailed structured clinical assessment at follow up visits and laboratory investigation results in suspected events of vitamin D toxicity.

[

Treatment diary and clinical assessment - at every follow up visit (at the end of 4th, 8th, 10th, 16th, 20th and 24th week) Laboratory assessment - baseline, 10th week and 24th week

]
5.

Changes in diet, physical activity, and sun exposure Method Diet - 3 day food diary Sun exposure - 3 day sun exposure diary Physical activity - International physical activity questionnaire (IPAQ) short version

[

Baseline, 10th and 24th week

]
6.

Changes in serum vitamin D levels following vitamin D supplementation Method - assessment of serum vitamin D level

[

At the point of recruitment (baseline) and, 10 weeks and 24 weeks after the intervention

]
7.

Changes in serum vitamin D levels following vitamin D supplementation Method - assessment of serum vitamin D level

[

At the point of recruitment (baseline) and, 10 weeks and 24 weeks after the intervention

]

Target number/sample size

40 (20 per each group)


Countries of recruitment

Sri Lanka


Anticipated start date

2026-08-20


Anticipated end date

2027-12-31


Date of first enrollment


Date of study completion


Recruitment status

Pending


Funding source

Rajarata University of Sri Lanka


Regulatory approvals

Not Applicable



State of Ethics Review Approval


Status

Approved


Date of Approval

2026-05-12


Approval number

ERC/2026/62


Details of Ethics Review Committee

Name: Ethics Review Committee of the Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka
Institutional Address:Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura
Telephone:+94 (0)25 2053633
Email: erc@med.rjt.ac.lk

Contact & Sponsor Information


Contact person for Scientific Queries/Principal Investigator

H.T.W. Weerakoon
Professor in Biochemistry
Department of Biochemistry, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura
025 2234461
070 5963808

harshitw@med.rjt.ac.lk

Contact Person for Public Queries

H.T.W. Weerakoon
Professor in Biochemistry
Department of Biochemistry, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura
025 2234461
070 5963808

harshitw@med.rjt.ac.lk


Primary study sponsor/organization

Rajarata University of Sri Lanka

Rajarata University of Sri Lanka, Mihintale
0252 266 643


https://www.rjt.ac.lk/

Secondary study sponsor (If any)

None





Trial Completion details


Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?

Yes


IPD sharing plan description

Following publication of the primary study results, de-identified individual participant data (IPD) underlying the findings reported in the text, tables, figures, and supplementary materials will be made available. The study protocol, statistical analysis plan, and relevant supporting documents will also be accessible upon reasonable request. Access to the de-identified dataset will be granted to qualified researchers whose proposed use of the data has been reviewed and approved by an independent review committee established for this purpose. Requests should include a brief research proposal outlining the intended use of the data and should be submitted to the Principal Investigator. Data sharing will commence following publication of the primary study findings and will be subject to applicable ethical and institutional requirements. All shared data will be fully de-identified to protect participant confidentiality and will be provided in Microsoft Excel format. To obtain data, proposals should be directed to harshitw@med.rjt.ac.lk.


Study protocol available

No


Protocol version and date

Not Available


Protocol URL

Not Available


Results summary available

No


Date of posting results


Date of study completion


Final sample size


Date of first publication


Link to results


Brief summary of results